Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

伊扎莫布 临时的 中期分析 医学 临床实习 临床试验 家庭医学 医学物理学 重症监护医学 内科学 历史 多发性骨髓瘤 Carfilzomib公司 蛋白酶体抑制剂 考古
作者
Chengcheng Fu,Xin Zhou,Junling Zhuang,Fan Zhou,Yuhua Li,Wen-Ming Chen,Rong Fu,Baijun Fang,Ting Niu,Hao Zhang,Lin Li,Depei Wu
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 12642-12644
标识
DOI:10.1182/blood-2022-165127
摘要

Background: China Food and Drug Administration formally approved the marketing of imported Ixazomib Citrate capsules in China on Apr 25, 2018. Pre-marketing clinical research was conducted restrictively in relapsed refractory multiple myeloma (RRMM) patients (pts) with multiple exclusion criteria and was not a comprehensive reflection of Ixazomib (IXA) real-world pts safety circumstances. Therefore, it is necessary to conduct a prospective post-marketing study to understand the gap between real clinical practice and pre-marketing clinical research. Aim: To report the characteristics and safety profile of IXA in Chinese multiple myeloma pts. We report an interim analysis (IA) of the INFINITE study. Method: INFINITE Study (NCT04328662) is a prospective, non-interventional, single-country study. Pts who have received at least one dose of IXA-based regimen treatment, with IXA < 3 months from their initial treatment or will be prescribed were included in the study. The enrolled pts with RRMM who received at least one dose of IXA-lenalidomide-dexamethasone (IRd) treatment were assigned to cohort 1. The newly diagnosed multiple myeloma (NDMM) and non-myeloma pts who have received at least one dose of IXA-based regimen, and RRMM pts who have received at least one dose of non-IRd IXA-based treatment were assigned to cohort 2. The primary outcome of this analysis is to evaluate the safety profile of IXA in a Chinese patient population. The secondary outcomes are effectiveness (ORR, DOT, TTNT, PFS, OS) of IXA in RRMM patients, safety, and efficacy based on clinical / disease characteristics as defined in cohort 1 and cohort 2. The time to event outcomes was estimated by the Kaplan-Meier method for incomplete observations and all statistical analysis were performed using SAS Enterprise Guide 8.3 software. Results: As of 31 Jan 2022 (data cut-off), 114 pts (Cohort 1 (n=6); Cohort 2 (n=108)) were enrolled and considered for data analysis. Among these, 10 pts had discontinued/withdrew from the study (1 pts due to disease progression, 2 pts due to death, 7 pts for other reasons). On overall evaluation at baseline 114 pts have been treated with IXA; median age 65 yrs [range 34-89]; 59.6% male; 35.1% with ISS III disease; 26.3% with R-ISS III disease; 62.3% with Durie-Salmon stage III; 32.5% with high-risk by Stratification of Mayo mSMART guidelines; 15.8% patient received stem cell transplantation. 78.9/17.5/7.0/ 2.6% pts had received prior treatment in L1/L2/L3/other respectively, before IXA. Further, 64 %pts received a V-based regimen including VCD/VRD/VTD in first-line therapy. Route of bortezomib administration was by intravenous injection and subcutaneous injection in 21.9% and 48.2% pts respectively, with the rest unknown. At baseline evaluation, 2.6/7.9/8.8/4.4% pts had achieved sCR/CR/VGPR/PR (Table 1). At the time of this IA, median follow-up is 4.01 month, 91.2% (104/114) of pts were still on therapy and enrollment is ongoing. Median duration from the start of IXA-based treatment was 3.5 months. The median time to next treatment was 3.8 months. Treatment-emergent adverse events (TEAEs) related to IXA were 43.0% and treatment-emergent serious adverse events (SAE) related to IXA were 4.4%. TEAEs leading to treatment discontinuation (temporary and permanent) were 7.9%. TEAEs leading to discontinuation of the study were 0.9%. SAEs leading to treatment discontinuation (temporary and permanent) were 2.6%. SAEs leading to discontinuation of the study were 0.9%. TEAE of special interest were 4.4%. TEAE with Outcome of Death is 1.8% (Table 2). Conclusion: The interim analysis results show characteristics in pts receiving IXA in real-world clinical practice. The safety profile of IXA in Chinese patients is consistent with the TOURMALINE-MM1-China Continuation Study. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助林夏采纳,获得10
2秒前
树池应助林夏采纳,获得10
2秒前
小鱼儿发布了新的文献求助10
4秒前
贝贝完成签到 ,获得积分10
4秒前
4秒前
xv完成签到,获得积分10
8秒前
guo发布了新的文献求助10
10秒前
10秒前
朱冰蓝完成签到 ,获得积分10
11秒前
NIHAO完成签到 ,获得积分10
12秒前
hyw010724完成签到,获得积分20
14秒前
千纸鹤完成签到,获得积分10
15秒前
仁爱听露完成签到 ,获得积分10
16秒前
KKKZ完成签到,获得积分10
17秒前
小鱼儿完成签到,获得积分10
17秒前
hyw010724发布了新的文献求助10
17秒前
19秒前
CipherSage应助guo采纳,获得10
21秒前
小二郎应助瑾玉采纳,获得10
22秒前
Christine完成签到 ,获得积分20
24秒前
领导范儿应助zly采纳,获得10
24秒前
是微微完成签到,获得积分10
24秒前
Akim应助hyw010724采纳,获得10
26秒前
Orange应助从容的白竹采纳,获得10
27秒前
30秒前
sun完成签到,获得积分10
30秒前
30秒前
31秒前
cctv18应助嘻嘻采纳,获得10
31秒前
热心的思天完成签到,获得积分10
32秒前
33秒前
安静幻枫应助Hongni采纳,获得20
34秒前
珍珠发布了新的文献求助10
36秒前
穆紫应助热心的思天采纳,获得10
37秒前
Logan发布了新的文献求助10
37秒前
Roach完成签到,获得积分10
38秒前
Negan完成签到,获得积分10
38秒前
39秒前
林夏完成签到,获得积分10
39秒前
39秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
Introduction to Modern Controls, with illustrations in MATLAB and Python 310
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3057308
求助须知:如何正确求助?哪些是违规求助? 2713802
关于积分的说明 7437402
捐赠科研通 2358921
什么是DOI,文献DOI怎么找? 1249607
科研通“疑难数据库(出版商)”最低求助积分说明 607190
版权声明 596314